Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.

Ming, Jian; Wu, Yuxia; Han, Rong; Xu, Xing; Waldeck, Reg; Hu, Shanlian

Ming, Jian; Wu, Yuxia; Han, Rong; Xu, Xing; Waldeck, Reg; Hu, Shanlian.

Afiliação

Ming J; Real World Solutions, IQVIA China, Shanghai, China. jming20@fudan.edu.cn.
Wu Y; School of Public Health, Fudan University, Shanghai, China. jming20@fudan.edu.cn.
Han R; Real World Solutions, IQVIA China, Shanghai, China.
Xu X; Medical Affairs, Pharmaceuticals, Bayer Healthcare Company Ltd, Beijing, China.
Waldeck R; Medical Affairs, Pharmaceuticals, Bayer Healthcare Company Ltd, Beijing, China.
Hu S; Bayer Healthcare Pharmaceuticals, 100 Bayer Blvd, Whippany, NJ, USA.

Adv Ther ; 40(3): 1087-1103, 2023 03.

Article em En | MEDLINE | ID: mdl-36630046

Assuntos

Neoplasias de Próstata Resistentes à Castração; Masculino; Humanos; Neoplasias de Próstata Resistentes à Castração/tratamento farmacológico; Neoplasias de Próstata Resistentes à Castração/patologia; Antagonistas de Androgênios/uso terapêutico; Análise Custo-Benefício; Androgênios/uso terapêutico

Palavras-chave

Cost-utility analysis; Darolutamide; Non-metastatic castration-resistant prostate cancer; Novel androgen receptor inhibitors; nmCRPC

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Etiology_studies / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google